FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200212881> ?p ?o ?g. }

• W4200212881 endingPage "S391" @default.
• W4200212881 startingPage "S390" @default.
• W4200212881 abstract "Abstract Background Global surveillance has identified emerging SARS-CoV-2 variants of concern (VOC) associated with increased transmissibility, disease severity, and resistance to neutralization by current vaccines under emergency use authorization (EUA). Here we assessed cross-immune responses of INO-4800 vaccinated subjects against SARS-CoV-2 VOCs. Methods We used a SARS-CoV-2 IgG ELISA and a pseudo neutralization assay to assess humoral responses, and an IFNγ ELISpot to measure cellular responses against SARS-CoV-2 VOC in subjects immunized with the DNA vaccine, INO-4800. Results IgG binding titers were not impacted between wild-type (WT) and B.1.1.7 or B.1.351 variants. An average 1.9-fold reduction was observed for the P.1 variant in subjects tested at week 8 after receiving two doses of INO-4800 (Figure 1a). We performed a SARS-CoV-2 pseudovirus neutralization assay using sera collected from 13 subjects two weeks after administration of a third dose of either 0.5 mg, 1 mg, or 2 mg of INO-4800. Neutralization was detected against WT and the emerging variants in all samples tested. The mean ID50 titers for the WT, B.1.1.7, B.1.351 and P.1. were 643 (range: 70-729), 295 (range: 46-886), 105 (range: 25-309), and 664 (range: 25-2087), respectively. Compared to WT, there was a 2.1 and 6.9-fold reduction for B.1.1.7 and B.1.351, respectively, while there was no difference between WT and the P.1 variant (Figure 1b). Next, we compared cellular immune responses to WT and SARS-CoV-2 Spike variants elicited by INO-4800 vaccination. We observed similar cellular responses to WT (median = 82.2 IQR = 58.9-205.3), B.1.1.7 (79.4, IQR = 38.9- 179.7), B.1.351 (80, IQR = 40.0-208.6) and P.1 (78.3, IQR = 53.1-177.8) Spike peptides (Figure 2). Conclusion INO-4800 vaccination induced neutralizing antibodies against all variants tested, with reduced levels detected against B.1.351. IFNγ T cell responses were fully maintained against all variants tested. Disclosures Viviane M. Andrade, PhD, Inovio Pharmaceuticals Inc. (Employee) Aaron Christensen-Quick, PhD, Inovio Pharmaceuticals, Inc (Employee) Joseph Agnes, PhD, Inovio (Employee, Shareholder) Jared Tur, PhD, Inovio (Employee) Charles C. Reed, PhD, Inovio Pharmaceuticals (Employee, Shareholder) Richa Kalia, MS, Inovio Pharmaceuticals (Employee, Other Financial or Material Support, I have stock options with Inovio Pharmaceuticals as an employee.) Idania Marrero, MD, PhD, Inovio Pharmaceuticals (Employee, Shareholder) Dustin Elwood, PhD, Inovio Pharmaceuticals (Employee) Katherine Schultheis, MSc, Inovio Pharmaceuticals (Employee) Emma Reuschel, PhD, Inovio Pharmaceuticals (Employee) Trevor McMullan, MSc, Inovio (Shareholder) Patrick Pezzoli, BS, Inovio (Employee) Kimberly A. Kraynyak, PhD, Inovio Pharmaceuticals (Employee, Other Financial or Material Support, Stock options) Albert Sylvester, MS, Inovio (Employee, Shareholder) Mammen P. Mammen Jr., MD, Inovio Pharmaceuticals (Employee) J Joseph Kim, PhD, Inovio (Employee) David Weiner, PhD, Inovio (Board Member, Grant/Research Support, Shareholder, I serve on the SAB in addition to the above activities) Trevor R. F. Smith, PhD, Inovio (Employee, Shareholder) Stephanie Ramos, PhD, Inovio Pharmaceuticals (Employee) Laurent Humeau, PhD, Inovio Pharmaceuticals (Employee) Jean Boyer, PhD, Inovio (Employee) Kate Broderick, PhD, Inovio (Employee)" @default.
• W4200212881 created "2021-12-31" @default.
• W4200212881 creator A5002399442 @default.
• W4200212881 creator A5008018388 @default.
• W4200212881 creator A5012363987 @default.
• W4200212881 creator A5014410261 @default.
• W4200212881 creator A5015377056 @default.
• W4200212881 creator A5015488396 @default.
• W4200212881 creator A5023265367 @default.
• W4200212881 creator A5024802271 @default.
• W4200212881 creator A5025867351 @default.
• W4200212881 creator A5044174713 @default.
• W4200212881 creator A5047272629 @default.
• W4200212881 creator A5049805385 @default.
• W4200212881 creator A5053501389 @default.
• W4200212881 creator A5058003355 @default.
• W4200212881 creator A5060301604 @default.
• W4200212881 creator A5061408818 @default.
• W4200212881 creator A5061630637 @default.
• W4200212881 creator A5062840115 @default.
• W4200212881 creator A5063348319 @default.
• W4200212881 creator A5067843924 @default.
• W4200212881 creator A5071139511 @default.
• W4200212881 creator A5071608389 @default.
• W4200212881 creator A5086923009 @default.
• W4200212881 creator A5091696726 @default.
• W4200212881 date "2021-11-01" @default.
• W4200212881 modified "2023-10-16" @default.
• W4200212881 title "578. INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants" @default.
• W4200212881 doi "https://doi.org/10.1093/ofid/ofab466.776" @default.
• W4200212881 hasPublicationYear "2021" @default.
• W4200212881 type Work @default.
• W4200212881 citedByCount "0" @default.
• W4200212881 crossrefType "journal-article" @default.
• W4200212881 hasAuthorship W4200212881A5002399442 @default.
• W4200212881 hasAuthorship W4200212881A5008018388 @default.
• W4200212881 hasAuthorship W4200212881A5012363987 @default.
• W4200212881 hasAuthorship W4200212881A5014410261 @default.
• W4200212881 hasAuthorship W4200212881A5015377056 @default.
• W4200212881 hasAuthorship W4200212881A5015488396 @default.
• W4200212881 hasAuthorship W4200212881A5023265367 @default.
• W4200212881 hasAuthorship W4200212881A5024802271 @default.
• W4200212881 hasAuthorship W4200212881A5025867351 @default.
• W4200212881 hasAuthorship W4200212881A5044174713 @default.
• W4200212881 hasAuthorship W4200212881A5047272629 @default.
• W4200212881 hasAuthorship W4200212881A5049805385 @default.
• W4200212881 hasAuthorship W4200212881A5053501389 @default.
• W4200212881 hasAuthorship W4200212881A5058003355 @default.
• W4200212881 hasAuthorship W4200212881A5060301604 @default.
• W4200212881 hasAuthorship W4200212881A5061408818 @default.
• W4200212881 hasAuthorship W4200212881A5061630637 @default.
• W4200212881 hasAuthorship W4200212881A5062840115 @default.
• W4200212881 hasAuthorship W4200212881A5063348319 @default.
• W4200212881 hasAuthorship W4200212881A5067843924 @default.
• W4200212881 hasAuthorship W4200212881A5071139511 @default.
• W4200212881 hasAuthorship W4200212881A5071608389 @default.
• W4200212881 hasAuthorship W4200212881A5086923009 @default.
• W4200212881 hasAuthorship W4200212881A5091696726 @default.
• W4200212881 hasBestOaLocation W42002128811 @default.
• W4200212881 hasConcept C14086860 @default.
• W4200212881 hasConcept C159047783 @default.
• W4200212881 hasConcept C159654299 @default.
• W4200212881 hasConcept C203014093 @default.
• W4200212881 hasConcept C2776090121 @default.
• W4200212881 hasConcept C2779053233 @default.
• W4200212881 hasConcept C2779261636 @default.
• W4200212881 hasConcept C32611913 @default.
• W4200212881 hasConcept C71924100 @default.
• W4200212881 hasConcept C8891405 @default.
• W4200212881 hasConceptScore W4200212881C14086860 @default.
• W4200212881 hasConceptScore W4200212881C159047783 @default.
• W4200212881 hasConceptScore W4200212881C159654299 @default.
• W4200212881 hasConceptScore W4200212881C203014093 @default.
• W4200212881 hasConceptScore W4200212881C2776090121 @default.
• W4200212881 hasConceptScore W4200212881C2779053233 @default.
• W4200212881 hasConceptScore W4200212881C2779261636 @default.
• W4200212881 hasConceptScore W4200212881C32611913 @default.
• W4200212881 hasConceptScore W4200212881C71924100 @default.
• W4200212881 hasConceptScore W4200212881C8891405 @default.
• W4200212881 hasIssue "Supplement_1" @default.
• W4200212881 hasLocation W42002128811 @default.
• W4200212881 hasLocation W42002128812 @default.
• W4200212881 hasLocation W42002128813 @default.
• W4200212881 hasLocation W42002128814 @default.
• W4200212881 hasOpenAccess W4200212881 @default.
• W4200212881 hasPrimaryLocation W42002128811 @default.
• W4200212881 hasRelatedWork W1972745941 @default.
• W4200212881 hasRelatedWork W1984647379 @default.
• W4200212881 hasRelatedWork W2002414632 @default.
• W4200212881 hasRelatedWork W2043102346 @default.
• W4200212881 hasRelatedWork W2063036651 @default.
• W4200212881 hasRelatedWork W2108106476 @default.
• W4200212881 hasRelatedWork W2126654882 @default.
• W4200212881 hasRelatedWork W2165262752 @default.
• W4200212881 hasRelatedWork W2354672636 @default.
• W4200212881 hasRelatedWork W4377695660 @default.
• W4200212881 hasVolume "8" @default.
• W4200212881 isParatext "false" @default.

• next